These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1980613)

  • 21. Neuroleptic-induced parkinsonism in older schizophrenics.
    Hoffman WF; Labs SM; Casey DE
    Biol Psychiatry; 1987 Apr; 22(4):427-39. PubMed ID: 2882787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology.
    Bak N; Ebdrup BH; Oranje B; Fagerlund B; Jensen MH; Düring SW; Nielsen MØ; Glenthøj BY; Hansen LK
    Transl Psychiatry; 2017 Apr; 7(4):e1087. PubMed ID: 28398342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of clozapine on cognitive function in schizophrenia.
    Lee MA; Thompson PA; Meltzer HY
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():82-7. PubMed ID: 7961582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia.
    Saykin AJ; Shtasel DL; Gur RE; Kester DB; Mozley LH; Stafiniak P; Gur RC
    Arch Gen Psychiatry; 1994 Feb; 51(2):124-31. PubMed ID: 7905258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia.
    Ho BC; Alicata D; Ward J; Moser DJ; O'Leary DS; Arndt S; Andreasen NC
    Am J Psychiatry; 2003 Jan; 160(1):142-8. PubMed ID: 12505813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroleptic prescription for Chinese schizophrenics in Hong Kong.
    Chiu H; Lee S; Leung CM; Wing YK
    Aust N Z J Psychiatry; 1992 Jun; 26(2):262-4. PubMed ID: 1353673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
    Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study.
    Rossi A; Mancini F; Stratta P; Mattei P; Gismondi R; Pozzi F; Casacchia M
    Acta Psychiatr Scand; 1997 Jan; 95(1):40-3. PubMed ID: 9051159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychotogenic drug use and neuroleptic response.
    Bowers MB; Mazure CM; Nelson JC; Jatlow PI
    Schizophr Bull; 1990; 16(1):81-5. PubMed ID: 1970670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.
    de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F
    Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive neuropsychological functioning in New Zealand Māori diagnosed with schizophrenia.
    Kake TR; Garrett N; Te Aonui M
    Aust N Z J Psychiatry; 2016 Jun; 50(6):566-76. PubMed ID: 26494850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased blink rates in schizophrenics. Influences of neuroleptics and psychopathology.
    Mackert A; Flechtner KM; Woyth C; Frick K
    Schizophr Res; 1991; 4(1):41-7. PubMed ID: 1672606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The predictive value of psychopathological subclassifications for the neuroleptic treatment outcome in schizophrenia.
    Jarema M; Kacperczyk J; Kruszynski S
    Psychopathology; 1991; 24(3):141-6. PubMed ID: 1684443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substance abuse and cognitive functioning in schizophrenia.
    Addington J; Addington D
    J Psychiatry Neurosci; 1997 Mar; 22(2):99-104. PubMed ID: 9074303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication compliance and substance abuse among schizophrenic patients.
    Pristach CA; Smith CM
    Hosp Community Psychiatry; 1990 Dec; 41(12):1345-8. PubMed ID: 1980483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profiling cognitive impairment in treatment-resistant schizophrenia patients.
    Frydecka D; Beszłej JA; Gościmski P; Kiejna A; Misiak B
    Psychiatry Res; 2016 Jan; 235():133-8. PubMed ID: 26706131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.